Smoking reduces the efficacy of belimumab in mucocutaneous lupus
(2018) In Expert Opinion on Biological Therapy 18(8). p.911-920- Abstract
Objectives: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE. Methods: We surveyed 62 SLE patients treated between 2011 and 2017. Evaluation included the mucocutaneous descriptors of SLEDAI-2K (rash, alopecia, mucosal ulcers; mcSLEDAI-2K), CLASI, the arthritis SLEDAI-2K descriptor (arSLEDAI-2K) and the 28-joint count. Results: mcSLEDAI-2K and CLASI activity decreased from baseline to month 6 and 12 (P < 0.001 for all). No worsening in CLASI damage was observed. Current or previous smokers displayed a higher probability of... (More)
Objectives: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE. Methods: We surveyed 62 SLE patients treated between 2011 and 2017. Evaluation included the mucocutaneous descriptors of SLEDAI-2K (rash, alopecia, mucosal ulcers; mcSLEDAI-2K), CLASI, the arthritis SLEDAI-2K descriptor (arSLEDAI-2K) and the 28-joint count. Results: mcSLEDAI-2K and CLASI activity decreased from baseline to month 6 and 12 (P < 0.001 for all). No worsening in CLASI damage was observed. Current or previous smokers displayed a higher probability of unchanged/worsened mcSLEDAI-2K compared to never smokers (OR: 6.4; 95% CI: 1.5–27.4; P = 0.012), also after adjustment for antimalarial agents. arSLEDAI-2K scores had decreased at month 6 (P < 0.001) and 12 (P < 0.001). Likewise, tender and swollen 28-joint counts had improved at month 6 (P = 0.010 and P < 0.001, respectively) and 12 (P = 0.001 for both). We observed no impact of smoking on belimumab efficacy in articular SLE. Conclusion: We observed a negative impact of smoking on the efficacy of belimumab in mucocutaneous SLE. In contrast, no impact of smoking on belimumab efficacy was seen in patients with articular manifestations.
(Less)
- author
- Parodis, Ioannis ; Gomez, Alvaro ; Frodlund, Martina ; Jönsen, Andreas LU ; Zickert, Agneta ; Sjöwall, Christopher ; Bengtsson, Anders A. LU and Gunnarsson, Iva
- organization
- publishing date
- 2018-08-03
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Belimumab, biological agents, drug efficacy, rheumatology, systemic lupus erythematosus
- in
- Expert Opinion on Biological Therapy
- volume
- 18
- issue
- 8
- pages
- 911 - 920
- publisher
- Ashley Publications
- external identifiers
-
- scopus:85049639213
- pmid:29958508
- ISSN
- 1471-2598
- DOI
- 10.1080/14712598.2018.1494719
- language
- English
- LU publication?
- yes
- id
- 248733f2-41bf-4f37-8028-57376112ea61
- date added to LUP
- 2018-07-20 10:47:26
- date last changed
- 2024-07-08 16:42:51
@article{248733f2-41bf-4f37-8028-57376112ea61, abstract = {{<p>Objectives: Recently, we demonstrated a negative impact of smoking on belimumab efficacy in patients with systemic lupus erythematosus (SLE). Here, we particularly investigated clinical effects of belimumab and a potential impact of smoking in mucocutaneous and articular SLE. Methods: We surveyed 62 SLE patients treated between 2011 and 2017. Evaluation included the mucocutaneous descriptors of SLEDAI-2K (rash, alopecia, mucosal ulcers; mcSLEDAI-2K), CLASI, the arthritis SLEDAI-2K descriptor (arSLEDAI-2K) and the 28-joint count. Results: mcSLEDAI-2K and CLASI activity decreased from baseline to month 6 and 12 (P < 0.001 for all). No worsening in CLASI damage was observed. Current or previous smokers displayed a higher probability of unchanged/worsened mcSLEDAI-2K compared to never smokers (OR: 6.4; 95% CI: 1.5–27.4; P = 0.012), also after adjustment for antimalarial agents. arSLEDAI-2K scores had decreased at month 6 (P < 0.001) and 12 (P < 0.001). Likewise, tender and swollen 28-joint counts had improved at month 6 (P = 0.010 and P < 0.001, respectively) and 12 (P = 0.001 for both). We observed no impact of smoking on belimumab efficacy in articular SLE. Conclusion: We observed a negative impact of smoking on the efficacy of belimumab in mucocutaneous SLE. In contrast, no impact of smoking on belimumab efficacy was seen in patients with articular manifestations.</p>}}, author = {{Parodis, Ioannis and Gomez, Alvaro and Frodlund, Martina and Jönsen, Andreas and Zickert, Agneta and Sjöwall, Christopher and Bengtsson, Anders A. and Gunnarsson, Iva}}, issn = {{1471-2598}}, keywords = {{Belimumab; biological agents; drug efficacy; rheumatology; systemic lupus erythematosus}}, language = {{eng}}, month = {{08}}, number = {{8}}, pages = {{911--920}}, publisher = {{Ashley Publications}}, series = {{Expert Opinion on Biological Therapy}}, title = {{Smoking reduces the efficacy of belimumab in mucocutaneous lupus}}, url = {{http://dx.doi.org/10.1080/14712598.2018.1494719}}, doi = {{10.1080/14712598.2018.1494719}}, volume = {{18}}, year = {{2018}}, }